Study Finds Birth Hypoxia May Increase ADHD Likelihood
January 27, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
plegridy
Synonyms :
peginterferon beta-1a
Class :
immunomodulator
Brand Name :
plegridy
Synonyms :
peginterferon beta-1a
Class :
immunomodulator
Dosage Forms & Strengths
Prefilled Subcutaneous injectable solution
63mcg/0.5ml and 94mcg/0.5ml
125mcg/0.5ml
Day 1:63mcg subcutaneous or intramuscular
Day 15:94mcg subcutaneous or intramuscular
From day 29: 125mcg subcutaneous or intramuscular once and every 14 days
Dosage Forms & Strengths
Safety and efficacy not established
Insufficient data available
may increase the toxic effect
may increase the toxic effect
It may diminish the therapeutic efficacy when combined with pegloticase
may enhance the adverse/toxic effect of interferons
Frequency defined:
>10%
Subcutaneous
Influenza-like illness
Headache
Pain at the injection site
Pruritis injection site
Erythema injection site
Pyrexia
Chills
Asthenia
Intramuscular
Headache
Pain at the injection site
Chills
Pain
1-10%
Subcutaneous
Increased AST
Increased ALT
Hyperthermia
Edema at the injection site
Hematoma at the injection site
Warmth at the injection site
rash at the injection site
Post-marketing reports
Non-infectious hepatitis
Anaphylaxis
Necrosis at the injection site
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: peginterferon beta-1a
Pronounced: [ peg-in-ter-FEAR-on-BAY-ta-1A ]
Why do we use peginterferon beta-1a?
Peginterferon beta-1a is a medication used to treat relapsing forms of multiple sclerosis (MS). It is a modified form of interferon beta-1a, a protein produced naturally by the body to help fight viral infections and other diseases. Peginterferon beta-1a works by modifying the immune system’s response to the body’s tissues, which can help reduce inflammation and damage to the central nervous system. It is usually given as an injection under the skin or into a muscle and is typically used with other MS medications
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
